The Journal of
Clinical Psychiatry

Empowering mental health professionals with peer-reviewed psychiatric research and insights

Back to top Open menu arrow
Current Issue Archives Authors Reviewers

Just Published

JCP
MAOI Antidepressants: A History Being Rewritten
Commentary

November 26, 2025

Members of the International MAOI Expert Group discuss historical use of MAOIs, consider their efficacy and safety, and underscore the importance of reassessing their place in treatment algorithms.
, , , et al
JCP
Triple Network Model–Based Functional Dysconnectivity in Young People With Major Affective Disorders With or Without Suicidal Ideation
Original Research

November 19, 2025

In young people with major affective disorders, suicidality is associated with extensive functional dysconnectivity in the triple networks (default mode network, salience network, and frontoparietal network).
, , , et al
JCP
Leadership in Clinical Psychopharmacology with Dr. Joe Goldberg
Podcast

November 18, 2025

Dr. Joe Goldberg discusses ASCP leadership, innovative psychopharmacology education, mentorship opportunities, and translating research into patient care.
,

Insightful. Evidence-based. Human-centered.

The Journal of Clinical Psychiatry Podcast

Explore the science, practice, and human side of mental health care. Hosted by Dr. Ben Everett, Senior Scientific Director at Physicians Postgraduate Press, the series brings together leading voices in psychiatry, neuroscience, and behavioral medicine to discuss the evidence shaping clinical care today.

Each episode features thoughtful conversations with JCP authors, academic experts, and frontline clinicians exploring disorders across the mental health continuum, from schizophrenia and mood disorders to anxiety, depression, and sleep-related conditions. By bridging research and real-world practice, the podcast delivers insights that empower psychiatrists, nurse practitioners, physician associates, and primary care clinicians to deliver better care for patients with mental illness.

Learn More

 

Explore Special Sections

Focus on Childhood and Adolescent Mental Health Early Career Psychiatrists Focus on Geriatric Psychiatry Focus on Psychotherapy Focus on Psychosis Focus on Suicide Focus on Women’s Mental Health
Cover of The Journal of Clinical Psychiatry, September 2025 issue, featuring article titles on postpartum distress, aripiprazole monohydrate injectables for schizophrenia and bipolar disorder, and other psychiatric topics.

Vol 86 • 2025 • Number 3

Read the Current Issue

Original Research

Postpartum Distress in Women With and Without ADHD

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report

Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report

In Memoriam

In Memoriam: Terence A. Ketter, MD

Narrative Review

Idiopathic Hypersomnia: Recognition and Management in Psychiatric Practice

Original Research

Predictors of Treatment Response to Adjunctive VNS Therapy in Major Depressive Disorder: A RECOVER Trial Report
View current Issue

Original Research

JCP
Effect of Adjuvant Metformin on Adherence to and Persistence of Treatment With SGAs in Nondiabetic Patients
Original Research

November 17, 2025

Use of metformin with second-generation antipsychotics (SGAs) was associated with improved adherence and persistence to SGAs at both 180- and 365-day follow-up in adults with Medicaid and commercial insurance.
,
JCP
Prevalence and 3-Year Outcomes of Mood Disorders
Original Research

November 12, 2025

Lower relapse rates of secondary mood disorders at 3 years suggest a more favorable course when the underlying cause is identified and treated.
, , , et al
JCP
Targeting Intolerance of Uncertainty during Pregnancy: A Randomized Controlled Trial to Prevent Postpartum Anxiety Disorders
Original Research

November 5, 2025

A 6-week CBT protocol targeting intolerance of uncertainty significantly reduced the risk of postpartum anxiety disorder onset versus care as usual, and patient satisfaction with treatment was high.
, , , et al

Review Articles

JCP
Burnout in Psychiatric Doctors Before and After the COVID-19 Pandemic
Meta-Analysis

September 29, 2025

The prevalence of burnout was 37.5% prior to the COVID-19 pandemic and 32.0% following the pandemic.
, ,
JCP
Treating PTSD in Military Populations
Meta-Analysis

March 24, 2025

Integrating psychotherapies and pharmacotherapies may address multiple dimensions of PTSD more effectively than monotherapies.
, , , et al
JCP
Changes in Cognition in Patients With Schizophrenia
Meta-Analysis

September 25, 2024

Only marginal improvements in cognition were seen over time; the greatest were achieved for patients with an illness duration shorter than 10 years.
, , , et al
JCP
Economic Impact of Cognitive Impairment and Negative Symptoms in Schizophrenia
Review Article

August 21, 2024

Patients with schizophrenia and cognitive impairment had a 100% increase in relapse-related hospitalizations and ER visits versus patients with no (or only mild) cognitive impairment.
, , , et al
JCP
Cognitive Effects of ECT in Schizophrenia: A Review
Review Article

June 5, 2024

ECT was not associated with any significant cognitive deficits in people with treatment-resistant schizophrenia across global cognition, attention, language, visuospatial function, and executive function domains. The majority of studies…
,
JCP
Interpersonal Psychotherapy for PTSD: A Critical Review
Review Article

May 29, 2024

This critical review will give clinicians confidence in considering IPT as an alternative to exposure treatments for posttraumatic stress disorder.

Read articles from ASCP Corner

ASCP Corner

Letters to the Editor

JCP
Exposure Therapy for Perinatal OCD: Navigating Evidence and Discomfort
Letter to the Editor

November 17, 2025

Although patients and providers must be prepared for the temporary distress associated with exposure and response prevention, it remains the most effective nonpharmacologic treatment for OCD.
, ,
JCP
From Today’s Observations to Tomorrow’s Standards in Women’s Psychiatry
Letter to the Editor

November 3, 2025

The authors comment on a recent study of treatment use and preference in women with mood disorders.
, ,
JCP
Context Matters in Treatment Preference of Women With Mood Disorders: Reply to Świeczkowski et al
Letter to the Editor

November 3, 2025

The authors reply to Świeczkowski and colleagues’ letter regarding their recent study
,
JCP
Racemic Ketamine vs Esketamine in Treatment-Resistant Depression: The Overlooked Role of Arketamine
Letter to the Editor

October 29, 2025

The authors comment on a recent chart review by Meisner et al.
,
JCP
Misleading Labeling of S-Methadone as a Novel N-Methyl-D-Aspartate Receptor Antagonist
Letter to the Editor

September 8, 2025

The authors comment on a recent study by Fava et al showing clinical evidence for a long-term antidepressant effect of esmethadone.
,
JCP
Reasons for Maintaining the Classification of Esmethadone as an Investigational Uncompetitive NMDAR Antagonist Rapid Antidepressant: Reply to Ferré and Michaelides
Letter to the Editor

September 8, 2025

The authors reply to Ferré and Michaelides’ letter commenting on their recent study of long-term esmethadone treatment in MDD.
, , , et al

Commentaries

JCP
Gender-Affirming Perinatal Psychiatry for Transgender and Gender Diverse People
Commentary

November 10, 2025

Considerations for providing perinatal psychiatric care to transgender and gender diverse patients are addressed
, ,
JCP
Beyond the Boxed Warning: A Call for Regulation of Psychiatry’s Most Teratogenic Drug
Commentary

October 6, 2025

The authors assert that while valproate remains invaluable for certain severe conditions, the high risk of teratogenicity means stringent safeguards are needed to regulate its use by individuals capable…
, , , et al
JCP
Why Getting Major Depression Right Matters—For Mothers, Babies, and All of Us
Commentary

September 24, 2025

Commenting on an FDA panel discussion on SSRI use during pregnancy, Dr Payne emphasizes the importance of precision when discussing treatments for mental health conditions.
JCP
Prioritizing Mental Health to Optimize Perinatal, Fetal, and Neonatal Outcomes
Commentary

September 24, 2025

Following an FDA panel discussion on use of SSRIs in pregnancy, the authors highlight the need for balanced conversations and shared decision-making accounting for the risks of untreated disease…
, , , et al
JCP
Ketamine and Esketamine: Is There a Meaningful Clinical Difference?
Commentary

September 22, 2025

The authors comment on a recent chart review by Meisner and colleagues.
,
JCP
The Emerging Science of Clinimetrics
Commentary

September 22, 2025

Dr Guidi highlights recent developments in clinimetric assessment strategies, with particular regard to the features of clinimetric measurements, the domains of clinimetrics, and implications for clinical research and practice.

More JCP Articles

JCP
Acetaminophen Use in Pregnancy and Neurodevelopmental Disorders in Offspring: A Reasoned Evaluation of Risk
Clinical and Practical Psychopharmacology

November 10, 2025

This article considers the background, questions, and evidence related to acetaminophen use in pregnancy and neurodevelopmental disorders in offspring, with reference to two recent large studies.
JCP
Real-World Implementation of Xanomeline-Trospium in Schizophrenia: A Consensus Panel Report
Academic Highlights

November 7, 2025

A consensus panel outlines strategies for real-world clinical implementation of xanomeline-trospium in the treatment of adult patients with schizophrenia
, , , et al
JCP
The Mission of JCP with Editor-in-Chief Marlene P. Freeman, MD
Podcast

November 4, 2025

Editor-in-Chief Dr. Marlene Freeman discusses the journal’s commitment to evidence-based psychiatry and advancing clinical care.
,
JCP
Esketamine Augmented With Dextromethorphan/Bupropion for Treatment Resistant Depression: A Case Series
Case Series

November 3, 2025

Three patients with TRD who had no or partial response to esketamine monotherapy as part of a clinical trial received augmentation with dextromethorphan/bupropion 45 mg/105 mg daily.
, , , et al
JCP
Retired US Military Veterans and Suicide Risk
Brief Report

October 29, 2025

This analysis found elevated suicide risk for medically retired service members and lower suicide risk for service members who retire based on time in service.
, , , et al
JCP
Neurocognition and Impulsivity in Veterans with Bipolar Spectrum Disorders: Suicide Attempters Versus Nonattempters
Original Research

October 29, 2025

Poorer working memory is associated with suicide attempt independent of depression, while verbal learning impairments associated with suicide attempt may be influenced by depression.
, , , et al
JCP
Brief Video Intervention to Increase Treatment-Seeking Intentions in Young Adults
Original Research

October 27, 2025

This brief video intervention was associated with greater increases in treatment-seeking intentions in people with self-reported psychiatric symptoms who were not previously engaged in the mental healthcare system and…
, , , et al
JCP
Evaluating the Transfer of Lurasidone Into Human Milk
Original Research

October 22, 2025

The relative infant dose of lurasidone, 1.16%, is below the standard 10% threshold for infant safety.
, ,
JCP
Autoimmune Diseases, Treatments, and Dementia Risk: A Population-Based Case-Control Study from Taiwan
Original Research

October 15, 2025

Thirteen autoimmune diseases were linked with an elevated dementia risk, particularly Behçet’s disease, multiple sclerosis, and lupus. Associations with vascular dementia were stronger than with Alzheimer’s disease.
, , , et al
JCP
Association of Immediate Postpartum Anxiety With Postpartum Depression
Original Research

October 15, 2025

The prevalence of immediate postpartum anxiety (IPPA) in this population was 24%, and 7.4% for severe anxiety. Among women with IPPA, 31.2% developed postpartum depression.
, , , et al
JCP
Brexpiprazole for the Treatment of Co-Occurring Schizophrenia and Substance Use Disorder
Original Research

October 13, 2025

This pilot trial suggests that brexpiprazole might be beneficial in reducing substance craving and use and improve quality of life in this difficult-to-treat patient population.
, , , et al
JCP
Treatment with (Es)ketamine in Catatonia: A Systematic Review of Case Reports
Brief Report

October 13, 2025

Recent evidence suggests that NMDA receptor antagonists, such as ketamine, may offer benefit in catatonia. This systematic review was conducted to evaluate the efficacy and safety of ketamine and…
, , , et al

Expert Consensus on Aripiprazole LAIs in Clinical Practice

Read the full report
Figure. Image of a syringe on two vials highlights aripiprazole monohydrate LAI clinical use in Bipolar I Disorder.

Subscribe to read
more articles

Subscribe